Photo courtesy of Merck.
Merck will tap Janux’s Tumor Activated T Cell Engager (TRACTr) tech to engineer new drug candidates against two cancer targets selected by Merck.

Photo courtesy of Merck. Merck will tap Janux’s Tumor Activated T Cell Engager (TRACTr) tech to engineer new drug candidates against two cancer targets selected by Merck.

Merck has entered an agreement with San Diego-based biotech Janux Therapeutics in a deal valued at more than $1 billion...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99